Accueil > Actualité
Actualite financiere : Actualite bourse

Novo Nordisk: growth hormone shows comparable efficacy

( - Novo Nordisk said that a phase 2 trial has showed that its experimental drug to treat children with growth hormone deficiency was as safe and effective as its currently available treatment.

The novel growth hormone derivative - which is being developed as a once-weekly treatment option - demonstrated comparable efficacy, safety and tolerability to once-daily injections of Novo's Norditropin after one year, with improved efficacy seen at the highest dose.

The 1-year results found that mean standard deviation annualised height velocity was statistically significantly higher with somapacitan compared to daily somatropin.

Copyright (c) 2019 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.